Prevalence of polymorphisms with significant resistance to NS5A inhibitors in treatment-naive patients with hepatitis Cvirus genotypes 1a and 3a in Sweden

Infectious Diseases

Volumn 47, Issue 8, 2015, Pages 555-562

  Lindström, Ida ^a   Kjellin, Midori ^a   Palanisamy, Navaneethan ^a,c   Bondeson, Kare ^a   Wesslén, Lars ^b   Lannergard, Anders ^a   Lennerstrand, Johan ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b GÄVLE HOSPITAL   (Sweden)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

baseline resistance; Hepatitis C virus; NS5A; polymorphism; prevalence

Indexed keywords

DACLATASVIR; NONSTRUCTURAL PROTEIN 5A; NONSTRUCTURAL PROTEIN 5A INHIBITOR; OMBITASVIR; ANTIVIRUS AGENT; BMS-790052; IMIDAZOLE DERIVATIVE; NS-5 PROTEIN, HEPATITIS C VIRUS; PROTEINASE INHIBITOR; VIRUS PROTEIN;

ARTICLE; GENE MUTATION; GENE SEQUENCE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HEPATITIS C VIRUS GENOTYPE 1A; HEPATITIS C VIRUS GENOTYPE 1B; HEPATITIS C VIRUS GENOTYPE 2B; HEPATITIS C VIRUS GENOTYPE 3A; HUMAN; MAJOR CLINICAL STUDY; NONHUMAN; PHENOTYPE; PREVALENCE; PROTEIN DOMAIN; SWEDEN; ANTAGONISTS AND INHIBITORS; ANTIVIRAL RESISTANCE; CHRONIC HEPATITIS C; DRUG EFFECTS; EPIDEMIOLOGY; GENETICS; HEPACIVIRUS; MISSENSE MUTATION; PHYLOGENY; POLYMERASE CHAIN REACTION; PROCEDURES; SEQUENCE ANALYSIS; VIROLOGY;

ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HEPATITIS C, CHRONIC; IMIDAZOLES; MUTATION, MISSENSE; PHYLOGENY; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; PREVALENCE; PROTEASE INHIBITORS; SEQUENCE ANALYSIS; SWEDEN; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84961742925     PISSN: 23744235     EISSN: None     Source Type: Journal    
DOI: 10.3109/23744235.2015.1028097     Document Type: Article

References (36)

1. Poveda E, Labarga P, Martin-Carbonero L, Fernandez-Montero JV, et al. Directly acting antivirals against hepatitis Cvirus. JAntimicrob Chemother 2011 ; 66 : 1673-86.
2. Te H S, Jensen D M. Epidemiology of hepatitis B and Cviruses: A global overview. Clin Liver Dis 2010 ; 14 : 1-21.
3. Duberg A, Janzon R, Bäck E, Ekdahl K, Blaxhult A. The epidemiology of hepatitis Cvirus infection in Sweden. Euro Surveill 2008 ; 13 : pii : 18882.
4. Bartenschlager R, Lohmann V, Penin F. The molecular and structural basis of advanced antiviral therapy for hepatitis Cvirus infection. Nat Rev Microbiol 2013 ; 11 : 482-96.
5. Lau GMG, Lau GML, Sugiyama M, Mizokami M. An updated analysis of hepatitis Cvirus genotypes and subtypes based on the complete coding region. Liver Int 2012 ; 32 : 339-45.
6. Simmonds P, Bukh J, Combet C, Deléage G, Enomoto N, Feinstone S, et al. Concensus proposals for a unified system of nomenclature of hepatitis Cvirus genotypes. Hepatology 2005 ; 42 : 962-73.
7. Alexopoulou A. Genetic heterogeneity of hepatitis Cvirus and its clinical significance. Ann Gastroenterol 2001 ; 14 : 261-72.
8. Schinazi R, Halfon P, Marcellin P, Asselah T. HCV directacting antiviral agents: The best interferon-free combinations. Liver Int 2014 ; 34(Suppl 1) : 69-78.
9. Palanisamy N, Danielsson A, Kokkula C, Yin H, Bondeson K, Wesslén L, et al. Implications of baseline polymorphisms for potential resistance to NS3 protease inhibitors in hepatitis Cvirus genotypes 1a, 2b and 3a. Antivir Res 2013 ; 99 : 12-17.
10. Belda O, Targett-Adams P. Small molecule inhibitors of the hepatitis Cvirus-encoded NS5A protein. Virus Res 2012 ; 170 : 1-14.
11. Ferenci P, Bernstein D, Lalezari J, Cohen D, Luo Y, Cooper C, et al. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. NEngl J Med 2014 ; 370 : 1983-992.
12. Kowdley K V, Gordon S C, Reddy K R, Rossaro L, Bernstein DE, Lawitz E, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. NEngl J Med 2014 ; 370 : 1879-888.
13. G ane EJ, Stedman CA, Hyland RH, Ding X, Svarovskaia E, Symonds WT, et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. NEngl J Med 2013 ; 368 : 34-44.
14. Lawitz E, Poordad F, Brainard D, Hyland R, An D, Symonds W, et al. Sofosbuvir in combination with PegIFN and ribavirin for 764 12 weeks provides high SVR rates in HCV-infected genotype 2 or 3 treatment-765 experienced patients with and without compensated cirrhosis: results from the LONESTAR-2 study. Presented at the 64rd annual meeting of the AASLD, Washington DC, USA ; 2013.
15. Coburn CA, Meinke PT, Chang W, Fandozzi CM, Graham DJ, Hu B, et al. Discovery of MK-8742: An HCV NS5A inhibitor with broad genotype activity. ChemMed-Chem 2013 ; 8 : 1930-40.
16. Gao M, Nettles RE, Belema M, Snyder LB, Nguyen VN, Fridell RA, et al. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature 2010 ; 465 : 96-100.
17. Powdrill M H, Tchesnokov E P, Kozak R A, Russell R S, Martin R, Svarovskaia ES, et al. Contribution of a mutational bias in hepatitis Cvirus replication to the genetic barrier in the development of drug resistance. Proc Natl Acad Sci USA 2011 ; 108 : 20509-13.
18. Bartels D J, Sullivan J C, Zhang E Z, Tigges AM, Dorrian J L, Meyer SD, et al. Hepatitis Cvirus variants with decreased sensitivity to direct-Acting antivirals (DAAs) were rarely observed in DAA-naive patients prior to treatment. JVirol 2013 ; 87 : 1544-53.
19. Danielsson A, Palanisamy N, Golbob S, Yin H, Blomberg J, Hedlund J, et al. Transmission of hepatitis Cvirus among intravenous drug users in the Uppsala region of Sweden. Infect Ecol Epidemiol 2014 ;Jan 15 : 4.
20. HCV Phenotype working group, HCV drug development advisory group. Clinically relevant HCV drug resistance mutations figure and tables. Ann Forum Collab HIV Res 2012 ; 14 : 1-10.
21. Poveda E, Wyles DL, Mena A, Pedreira JD, Castro-Iglesias A, Cachay E. Update on hepatitis Cvirus resistance to directacting antiviral agents. Antivir Res 2014 ; 108 : 181-91.
22. Fridell RA, Qiu D, Wang C, Valera L, Gao M. R esistance analysis of the hepatitis Cvirus NS5A inhibitor BMS-790052 in an in vitro replicon system. Antimicrob Agents Chemother 2010 ; 54 : 3641-50.
23. Krishnan P, Beyer J, Mistry N, Koev G, Reisch T, Mondal R, et al. Antiviral activity and resistance profiles for ABT-267, anovel HCV NS5A inhibitor, in vitro and during 3-day monotherapy in HCV genotype-1 (GT1)-infected treatmentna ï ve subjects. Abstract 1881 presented at the 63rd annual meeting of the AASLD, Boston, USA ; 2012.
24. Wang C, Valera L, Jia L, Kirk MJ, Gao M, Fridell RA. In vitro activity of daclatasvir on hepatitis Cvirus genotype 3 NS5A. Antimicrob Agents Chemother 2012 ; 57 : 611-13.
25. Sarrazin C, Zeuzem S. Resistance to direct antiviral agents in patients with hepatitis Cvirus infection. Gastroenterology 2010 ; 138 : 447-62.
26. McCormick A L, Wang L, Garcia-Diaz A, Macartney MJ, Webster DP, Haque T. Prevalence of baseline polymorphisms for potential resistance to NS5A inhibitors in drug-naive individuals infected with hepatitis C genotypes 1-4. Antivir Ther 2015 ; 20 : 81-5.
27. Paolucci S, Fiorina L, Mariani B, Gulminetti R, Novati S, Barbarini G, et al. Naturally occurring resistance mutations to inhibitors of HCV NS5A region and NS5B polymerase in DAA treatment-na ï ve patients. Virol J 2013 ; 10 : 355.
28. Hernandez D, Zhou N, Ueland J, Monikowski A, McPhee F. Natural prevalence of NS5A polymorphisms in subjects infected with hepatitis Cvirus genotype 3 and their effects on the antiviral activity of NS5A inhibitors. J Clin Virol 2013 ; 57 : 13-18.
29. Vermehren J, Sarrazin C. The role of resistance in HCV treatment. Best Pract Res Clin Gastroenterol 2012 ; 26 : 487-503.
30. Wang C, Huang H, Valera L, Sun JH, OBoyle DR 2 nd, Nower PT, et al. Hepatitis Cvirus RNA elimination and development of resistance in replicon cells treated with BMS-790052. Antimicrob Agents Chemother 2012 ; 56 : 1350-8.
31. McPhee F. Phenotypic assay: Technical and translational considerations. Presented at the 10th HCV DrAG meeting : issues in HCV drug development, Amsterdam, The Netherlands ; 2013.
32. Karino Y, Toyota J, Ikeda K, Suzuki F, Chayama K, Kawakami Y, et al. Characterization of virologic escape in hepatitis Cvirus genotype 1b patients treated with the directacting antivirals daclatasvir and asunaprevir. JHepatol 2013 ; 58 : 646-54.
33. Everson GT, Thuluvath PJ, Lawitz E, Hassanein T, Rodriguez-Torres M, Hawkins T, et al. All-oral combination of daclatasvir, dsunaprevir, and BMS-791325 for HCV genotype 1 infection. Abstract 25 presented at the 21st annual meeting of the CROI, Boston, USA ; 2014.
34. Sulkowski M S, Gardiner D F, Rodriguez-Torres M, Reddy KR, Hassanein T, Jacobson I, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. NEngl J Med 2014 ; 370 : 211-21.
35. Dvory-Sobol H, Doehle B, Svarovskaia E, McCarville J F, Pang P, Afdhal N, et al. The prevalence of HCV NS5A, nucleoside and protease inhibitor resistance associated variants and the effects on treatment with ledipasvir/sofosbuvir-RBV in the phase 3 ION Studies. Antivir Ther 2014;19(Suppl 1):A38. Available at : http://www.natap. org/2014/ResisWksp/ResisWksp-07.htm
36. Nelson D R, Cooper J N, Lalezari J P, Lawitz E, Pockros P J, Gitlin N, et al. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis Cvirus genotype 3 infection: ALLY-3 Phase 3 study. Hepatology 2015 Jan 23 [Epub ahead of print].